Item 5.07. Submission of Matters to a Vote of Security Holders.

On August 17, 2021, Aerpio Pharmaceuticals, Inc. (the "Company") held a Special Meeting of Stockholders (the "Special Meeting") in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company's Definitive Proxy Statement filed on July 8, 2021 with the Securities and Exchange Commission under Section 14(a) of the Securities Exchange Act of 1934, as amended (the "Proxy Statement"). As of July 6, 2021, the record date for the Special Meeting, the number of shares of the Company's common stock, $0.0001 par value per share ("Common Stock"), outstanding and entitled to vote at the Special Meeting was 47,477,084. The number of shares of Common Stock present or represented by valid proxy at the Special Meeting was 33,092,898 thus establishing a quorum for the Special Meeting. Each share of Common Stock was entitled to one vote with respect to matters submitted to the Company's stockholders at the Special Meeting. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Special Meeting.

Proposal 1

The Company's stockholders approved the issuance of Common Stock pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2021, by and among the Company, Aspen Merger Subsidiary, Inc., a wholly-owned subsidiary of the Company, and Aadi Bioscience, Inc., and the issuance of Common Stock and pre-funded warrants (the "Pre-Funded Warrants") to acquire Common Stock (the "PIPE Financing") pursuant to the subscription agreements, dated as of May 16, 2021, by and among the Company and the purchasers named therein, and the resulting change of control of the Company pursuant to the rules of The Nasdaq Stock Market LLC. The results of the approval were as follows:





   For       Against   Abstain   Broker Non-Votes
32,166,851   918,573    7,474           -


Proposal 2

The Company's stockholders approved an amended and restated certificate of incorporation of the Company, including to effect a reverse stock split at a ratio of a whole number between and including 1-for-five and 1-for-fifteen (the "Reverse Stock Split"). The results of the approval were as follows:





   For        Against    Abstain   Broker Non-Votes
32,055,108   1,026,411   11,379           -


Proposal 3

The Company's stockholders approved an incentive award plan. The results of the approval were as follows:





   For        Against    Abstain   Broker Non-Votes
27,444,114   5,613,175   35,609           -


Proposal 4

The Company's stockholders approved an employee stock purchase plan. The results of the approval were as follows:





   For        Against    Abstain   Broker Non-Votes
27,622,171   5,449,019   21,708           -


Proposal 5

The Company's stockholders approved an adjournment or postponement, if necessary, of the Special Meeting for the purpose of soliciting additional proxies to approve Proposal 1 and/or Proposal 2. Although Proposal 5 was approved, the adjournment or postponement of the Special Meeting was not necessary because there were sufficient votes at the time of the Special Meeting to approve Proposal 1 and Proposal 2. The results of the approval were as follows:





   For        Against    Abstain   Broker Non-Votes
31,322,779   1,747,272   22,847           -

No other matters were submitted to or voted on by the Company's stockholders at the Special Meeting.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses